Bicycle Therapeutics Financials - Benzinga

Bicycle Therapeutics PLC

BCYCNASDAQ

Trade with Public

Trade with Public

$3.99

-0.01-0.25%

At close: Aug 18, 5:00 PM EST

$3.99

N/A

After Hours: 4:01 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Bicycle Therapeutics Financials

Bicycle Therapeutics (BCYC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.59) by 22.03 percent. This is a 36.84 percent increase over losses of $(1.14) per

Benzinga Newsdesk

PRO
Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.73) by 19.18 percent. This is a 1.14 percent increase over losses of $(0.88) per share

Benzinga Newsdesk

PRO
Bicycle Therapeutics Q4 EPS $(0.29) Beats $(1.00) Estimate, Sales $47.955M Up YoY From $3.708M

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(1.00) by 70.97 percent. This is a 61.33 percent increase over losses of $(0.75) per share

Benzinga Newsdesk

PRO
Bicycle Therapeutics Q3 EPS $(0.85) Beats $(1.09) Estimate, Sales $11.734M Beat $7.333M Estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.09) by 22.37 percent. This is a 14.86 percent decrease over losses of $(0.74) per share

Benzinga Newsdesk

PRO
Bicycle Therapeutics' Cash And Cash Equivalents Of $721.5M As Of June 30, 2025, With Expected Financial Runway Extended Into 2028

Benzinga Newsdesk

PRO
Bicycle Therapeutics Q2 EPS $(1.14) Misses $(0.97) Estimate, Sales $2.920M Miss $8.714M Estimate

Benzinga Newsdesk